Astrazeneca has been given the all-clear to buy rare disease drug maker Alexion in a blockbuster £28billion deal.
Astrazeneca has been given the all-clear to buy rare disease drug maker Alexion in a blockbuster £28billion deal. The Competition and Markets... Read More
Alexion acquisition of Achillion: A 1 Billion Pharma Strategic Deal
Posted on21 Oct 2019
TagsAchillion, acquisition in pharma, Alexion Pharmaceuticals, global pharma deals, pharma deal, pharma strategic deal
Comments0
Achillion focuses on the development of oral small-molecule Factor D inhibitors to treat people with rare diseases affecting the ‘complement system’, such... Read More
Alexion’s inlicensing deal for Amyloidosis Candidate In Japan
Posted on12 Sep 2019
Comments0
Alexion Pharmaceuticals announced a license agreement with BridgeBio Pharma’s subsidiary Eidos Therapeutics. Per the terms of the deal, Alexion will obtain an... Read More
Novozyme Ranked 1 in among top 20 global biotech employers for 2015
Posted on03 Nov 2015
TagsAbbott, AbbVie, Alexion Pharmaceuticals, Bayer, Biocon, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, gilead, Merck KGaA, Moderna Therapeutics, Monsanto Company, Novozymes, Regeneron Pharmaceuticals Novo Nordisk, Roche—excluding Genentech, Top 10 Biotech company globally, vertex pharmaceuticals
Comments0
Novozymes has earned 1st rank globally on top biotechnology employers in the world as ranked by American Association for the Advancement of Science (AAAS).... Read More